Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 2003, 63: 11-30. 10.3322/caac.21166.
Article
Google Scholar
World Health Organization: The global burden of disease: 2004 update. In [http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/]
Johansson M, Denardo DG, Coussens LM: Polarized immune responses differentially regulate cancer development. Immunol Rev. 2008, 222: 145-154. 10.1111/j.1600-065X.2008.00600.x.
Article
PubMed Central
CAS
PubMed
Google Scholar
Riddell SR: Finding a place for tumor-specific T cells in targeted cancer therapy. J Exp Med. 2004, 200: 1533-1537. 10.1084/jem.20042004.
Article
PubMed Central
CAS
PubMed
Google Scholar
Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD: Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002, 3: 991-998. 10.1038/ni1102-991.
Article
CAS
PubMed
Google Scholar
Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y: Cytokines in cancer immunity and immunotherapy. Immunol Rev. 2004, 202: 275-293. 10.1111/j.0105-2896.2004.00199.x.
Article
CAS
PubMed
Google Scholar
Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH: Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001, 61: 4766-4772.
CAS
PubMed
Google Scholar
Okita R, Saeki T, Takashima S, Yamaguchi Y, Toge T: CD4 + CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer. Oncol Rep. 2005, 14: 1269-1273.
CAS
PubMed
Google Scholar
Taams LS, Smith J, Rustin MH, Salmon M, Poulter LW, Akbar AN: Human anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-prone population. Eur J Immunol. 2001, 31: 1122-1131. 10.1002/1521-4141(200104)31:4<1122::AID-IMMU1122>3.0.CO;2-P.
Article
CAS
PubMed
Google Scholar
Petersen RP, Campa MJ, Sperlazza J, Conlon D, Joshi MB, Harpole DH, Patz EF: Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer. 2006, 107: 2866-2872. 10.1002/cncr.22282.
Article
PubMed
Google Scholar
Shimizu K, Nakata M, Hirami Y, Yukawa T, Maeda A, Tanemoto K: Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol. 2010, 5: 585-590.
Article
PubMed
Google Scholar
Schneider T, Kimpfler S, Warth A, Schnabel PA, Dienemann H, Schadendorf D, Hoffmann H, Umansky V: FOXP3+ regulatory T cells and natural killer cells distinctly infiltrate primary tumors and draining lymph nodes in pulmonary adenocarcinoma. J Thorac Oncol. 2011, 6: 432-438. 10.1097/JTO.0b013e31820b80ca.
Article
PubMed
Google Scholar
Lundy SK: Killer B lymphocytes: the evidence and the potential. Inflamm Res. 2009, 58: 345-357. 10.1007/s00011-009-0014-x.
Article
CAS
PubMed
Google Scholar
Vitale G, Mion F, Pucillo C: Regulatory B cells: evidence, developmental origin and population diversity. Mol Immunol. 2010, 48: 1-8. 10.1016/j.molimm.2010.09.010.
Article
CAS
PubMed
Google Scholar
Watanabe R, Ishiura N, Nakashima H, Kuwano Y, Okochi H, Tamaki K, Sato S, Tedder TF, Fujimoto M: Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbates systemic autoimmunity. J Immunol. 2010, 184: 4801-4809. 10.4049/jimmunol.0902385.
Article
PubMed Central
CAS
PubMed
Google Scholar
DiLillo DJ, Matsushita T, Tedder TF: B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann N Y Acad Sci. 2010, 1183: 38-57. 10.1111/j.1749-6632.2009.05137.x.
Article
CAS
PubMed
Google Scholar
Olkhanud PB, Damdinsuren B, Bodogai M, Gress RE, Sen R, Wejksza K, Malchinkhuu E, Wersto RP, Biragyn A: Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4 T cells to T-regulatory cells. Cancer Res. 2011, 71: 3505-3515. 10.1158/0008-5472.CAN-10-4316.
Article
PubMed Central
CAS
PubMed
Google Scholar
Grivennikov SI, Greten FR, Karin M: Immunity, inflammation, and cancer. Cell. 2010, 140: 883-899. 10.1016/j.cell.2010.01.025.
Article
PubMed Central
CAS
PubMed
Google Scholar
Bull M, Lee D, Stucky J, Chiu YL, Rubin A, Horton H, McElrath MJ: Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials. J Immunol Methods. 2007, 322: 57-69. 10.1016/j.jim.2007.02.003.
Article
PubMed Central
CAS
PubMed
Google Scholar
Hein F, Massin F, Cravoisy-Popovic A, Barraud D, Levy B, Bollaert PE, Gibot S: The relationship between CD4 + CD25 + CD127- regulatory T cells and inflammatory response and outcome during shock states. Crit Care. 2010, 14: R19-10.1186/cc8876.
Article
PubMed Central
PubMed
Google Scholar
Iwata Y, Matsushita T, Horikawa M, DiLillo DJ, Yanaba K, Venturi GM, Szabolcs PM, Magro CM, Williams AD, Hall RP, St Clair EW, Tedder TF: Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood. 2011, 117: 530-541. 10.1182/blood-2010-07-294249.
Article
PubMed Central
CAS
PubMed
Google Scholar
Yanaba K, Bouaziz J-D, Haas KM, Poe JC, Fujimoto M, Tedder TF: A regulatory B-cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity. 2008, 28: 639-650. 10.1016/j.immuni.2008.03.017.
Article
CAS
PubMed
Google Scholar
Woo EY, Yeh H, Chu CS, Schleinger K, Carroll RG, Riley JL, Kaiser LR, June CH: Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol. 2002, 168: 4272-4276. 10.4049/jimmunol.168.9.4272.
Article
CAS
PubMed
Google Scholar
Ju S, Qiu H, Zhou X, Zhu B, Lv X, Huang X, Li J, Zhang Y, Ge Y, Johnson DE, Ju S, Shu Y: CD13 + CD4 + CD25hi regulatory T cells exhibit higher suppressive function and increase with tumor stage in non-small cell lung cancer patients. Cell Cycle. 2009, 8: 2578-2585. 10.4161/cc.8.16.9302.
Article
CAS
PubMed
Google Scholar
Karin M: Nuclear factor-kappaB in cancer development and progression. Nature. 2006, 438: 820-827.
Google Scholar
Sallusto F, Geginat J, Lanzavecchia A: Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004, 22: 745-763. 10.1146/annurev.immunol.22.012703.104702.
Article
CAS
PubMed
Google Scholar
Seddiki N, Santner-Nanan B, Tangye SG, Alexander SI, Solomon M, Lee S, Nanan R, Fazekas de Saint Groth B: Persistence of naïve CD45RA + regulatory T cells in adult life. Blood. 2006, 107: 2830-2838. 10.1182/blood-2005-06-2403.
Article
CAS
PubMed
Google Scholar
Moran CJ, Arenberg DA, Huang CC, Giordano TJ, Thomas DG, Misek DE, Chen G, Iannettoni MD, Orringer MB, Hanash S, Beer DG: RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin Cancer Res. 2002, 8: 3803-3812.
CAS
PubMed
Google Scholar
Konishi T, Okabe H, Katoh H, Fujiyama Y, Mori A: Macrophage inflammatory protein-1 alpha expression in non-neoplastic and neoplastic lung tissue. Vichows Arch. 1996, 428: 107-111. 10.1007/BF00193938.
Article
CAS
Google Scholar
Wang XD, Peer D, Petersen B: Molecular and Cellular Therapies: New challenges and opportunities. Mol Cell Therap. 2013, 1: 1-10.1186/2052-8426-1-1.
Article
Google Scholar
Wu XD, Chen LN, Wang XD: Network biomarkers, interaction networks and dynamical network biomarkers in respiratory diseases. Clin Transl Med. 2014, 3: 16-10.1186/2001-1326-3-16.
Article
PubMed Central
PubMed
Google Scholar
Zhu Z, Wang DC, Popescu LM, Wang XD: Single-cell transcriptome in the identification of disease biomarkers: opportunities and challenges. J Transl Med. 2014, 12: 212-10.1186/s12967-014-0212-3.
Article
PubMed Central
PubMed
Google Scholar
Wang XD: Role of clinical bioinformatics in the development of network-based Biomarkers. J Clin Bioinforma. 2011, 1: 28-10.1186/2043-9113-1-28.
Article
PubMed Central
PubMed
Google Scholar
Wu DJ, Zhu BJ, Wang XD: Metabonomics-based omics study and atherosclerosis. J Clin Bioinforma. 2011, 1: 30-10.1186/2043-9113-1-30.
Article
PubMed Central
CAS
PubMed
Google Scholar
Wang XD, Liotta L: Clinical bioinformatics: a new emerging science. J Clin Bioinforma. 2011, 1: 1-10.1186/2043-9113-1-1.
Article
PubMed Central
PubMed
Google Scholar
Taylor MA, Schiemann WP: Therapeutic opportunities for targeting microRNAs in cancer. Mol Cell Therap. 2014, 2: 30-10.1186/2052-8426-2-30.
Article
Google Scholar
Donzelli S, Mori F, Biagioni F, Bellissimo T, Pulito C, Muti P, Strano S, Blandino G: MicroRNAs: short non-coding players in cancer chemoresistance. Mol Cell Therap. 2014, 2: 16-10.1186/2052-8426-2-16.
Article
Google Scholar
Frantzi M, Bhat A, Latosinska A: Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development. Clin Transl Med. 2014, 3: 7-10.1186/2001-1326-3-7.
Article
PubMed Central
PubMed
Google Scholar